Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 27 04:00PM ET
1.87
Dollar change
+0.03
Percentage change
1.63
%
Index- P/E- EPS (ttm)- Insider Own0.27% Shs Outstand82.99M Perf Week-1.58%
Market Cap155.19M Forward P/E- EPS next Y-0.81 Insider Trans0.00% Shs Float82.77M Perf Month1.08%
Income- PEG- EPS next Q-0.22 Inst Own21.47% Short Float1.32% Perf Quarter17.61%
Sales- P/S- EPS this Y20.70% Inst Trans-17.36% Short Ratio1.99 Perf Half Y50.81%
Book/sh4.11 P/B0.45 EPS next Y-1.07% ROA- Short Interest1.09M Perf Year-39.29%
Cash/sh4.93 P/C0.38 EPS next 5Y26.00% ROE- 52W Range1.16 - 3.88 Perf YTD-1.58%
Dividend Est.- P/FCF- EPS past 5Y-17.40% ROI- 52W High-51.80% Beta1.11
Dividend TTM- Quick Ratio4.64 Sales past 5Y1209.00% Gross Margin- 52W Low61.21% ATR (14)0.12
Dividend Ex-Date- Current Ratio4.64 EPS Y/Y TTM- Oper. Margin-1527.18% RSI (14)54.38 Volatility6.02% 6.59%
Employees318 Debt/Eq0.03 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price7.25
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q814.57% Payout- Rel Volume0.89 Prev Close1.84
Sales Surprise- EPS Surprise-0.72% Sales Q/Q15398.08% EarningsMar 14 AMC Avg Volume548.68K Price1.87
SMA203.40% SMA505.17% SMA200-3.53% Trades Volume486,976 Change1.63%
Date Action Analyst Rating Change Price Target Change
Dec-09-21Initiated Siebert Williams Shank Buy $96
Jun-02-21Initiated Daiwa Securities Buy
Mar-15-21Initiated Needham Buy $75
Mar-03-21Reiterated H.C. Wainwright Buy $55 → $75
Feb-25-21Initiated Piper Sandler Overweight $75
Dec-07-20Initiated H.C. Wainwright Buy $55
Jul-27-20Initiated Cantor Fitzgerald Overweight $50
Feb-12-20Initiated China Renaissance Buy
Feb-11-20Initiated Jefferies Buy $16
Mar-14-24 05:00PM
Mar-07-24 10:03AM
Feb-21-24 01:56AM
Feb-07-24 08:28AM
06:29AM
06:00AM Loading…
06:00AM
Nov-06-23 08:00AM
Nov-02-23 08:00AM
Nov-01-23 08:00AM
Oct-16-23 08:00AM
Oct-10-23 08:00AM
Oct-05-23 05:17PM
Sep-22-23 05:03PM
Sep-05-23 08:00AM
Aug-18-23 10:55AM
10:30PM Loading…
Aug-17-23 10:30PM
06:00AM
05:25AM
Aug-08-23 08:00AM
Jul-07-23 06:35PM
Jul-05-23 08:00AM
Jun-22-23 08:00AM
Jun-11-23 10:31AM
May-26-23 10:00AM
May-25-23 05:01PM
May-01-23 08:00AM
Apr-26-23 09:16AM
Apr-25-23 01:46AM
Apr-24-23 09:00AM
Apr-05-23 10:59AM
10:51AM Loading…
10:51AM
Mar-31-23 06:30AM
Mar-20-23 08:00AM
Mar-10-23 02:26AM
Mar-09-23 05:49AM
Mar-07-23 08:02AM
Feb-25-23 07:14AM
Jan-29-23 07:07AM
Jan-02-23 06:14AM
Nov-12-22 08:21AM
Nov-03-22 09:01AM
Oct-05-22 08:00AM
Sep-13-22 08:00AM
Sep-10-22 09:00AM
Sep-06-22 08:00AM
Aug-30-22 06:00AM
Aug-23-22 09:13AM
Aug-20-22 08:26AM
Aug-19-22 09:00AM
Aug-18-22 12:38PM
Aug-17-22 03:24PM
10:19AM
Aug-02-22 09:04AM
Jul-22-22 08:00AM
Jul-18-22 08:00AM
Jul-06-22 08:00AM
Jun-23-22 08:00AM
Jun-15-22 08:30AM
May-31-22 08:00AM
May-26-22 05:01PM
May-19-22 08:00AM
May-12-22 06:16AM
May-05-22 08:00AM
Apr-28-22 04:01PM
Apr-20-22 08:25PM
Mar-31-22 08:00AM
Mar-29-22 06:10AM
Mar-25-22 08:00PM
Mar-18-22 08:00AM
Mar-15-22 02:22PM
08:00AM
Mar-09-22 08:00AM
Mar-03-22 08:00AM
Mar-01-22 09:28AM
Feb-26-22 12:58PM
Feb-08-22 09:38AM
Jan-28-22 08:00AM
Jan-27-22 01:38PM
Jan-18-22 08:00AM
Jan-14-22 08:00AM
Jan-12-22 08:00AM
Jan-06-22 08:00AM
Jan-04-22 09:32AM
Dec-27-21 08:00AM
Dec-20-21 08:00AM
Dec-15-21 08:00AM
Dec-14-21 06:00AM
Dec-09-21 08:00AM
Dec-07-21 10:26AM
08:00AM
Dec-03-21 08:00AM
Nov-15-21 11:00AM
Nov-13-21 08:41AM
Nov-10-21 08:19AM
07:20AM
04:30AM
Nov-09-21 08:05AM
Nov-08-21 08:30AM
08:00AM
08:00AM
I-Mab operates as a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel or differentiated biologics to treat diseases with unmet medical needs, particularly cancers and autoimmune disorders. The company was founded by Jingwu Zang on June 30, 2016 and is headquartered in Pudong, China.